Neuren Pharmaceuticals (ASX:NEU) said its partner, Nasdaq-listed Acadia Pharmaceuticals, secured marketing authorization from Health Canada for its Daybue drug developed to treat Rett syndrome in adult and pediatric patients aged two and older, according to a Thursday filing with the Australian Securities Exchange.
Rett syndrome is a genetic neurological disorder causing progressive motor skills and language loss.
The approval was the first received outside the US, said Neuren Chief Executive Jon Pilcher.
Neuren Pharmaceuticals shares rose more than 2% in morning trade on Thursday.
Price (AUD): $12.99, Change: $+0.29, Percent Change: +2.28%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。